^
+ Follow SUIS Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 582518
                    [Title] => Hungry gourmand
                    [Summary] => 

MILLIE: “Je suis gourmand.

[DatePublished] => 2010-06-10 00:00:00 [ColumnID] => 134170 [Focus] => 0 [AuthorID] => 1805395 [AuthorName] => Millie and Karla Reyes [SectionName] => Food and Leisure [SectionUrl] => food-and-leisure [URL] => ) [1] => Array ( [ArticleID] => 267647 [Title] => Evidence mounts for gut worm therapy [Summary] => Two sets of findings presented at the 2004 Digestive Disease Week meeting lend strength to the belief that helminthic therapy may be a highly effective treatment for inflammatory bowel disease (IBD) in a double-blind, randomized, placebo-controlled study that included 54 patients with ulcerative colitis (UC), approximately 50 percent of the patients responded to Trichurisuis ova therapy.

In addition, in an open-label study of 29 patients with refractory Crohn’s disease (CD), 79.3 percent of the subjects responded to treatment, and 72.4 percent achieved clinical remission. [DatePublished] => 2005-01-02 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) ) )
SUIS
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 582518
                    [Title] => Hungry gourmand
                    [Summary] => 

MILLIE: “Je suis gourmand.

[DatePublished] => 2010-06-10 00:00:00 [ColumnID] => 134170 [Focus] => 0 [AuthorID] => 1805395 [AuthorName] => Millie and Karla Reyes [SectionName] => Food and Leisure [SectionUrl] => food-and-leisure [URL] => ) [1] => Array ( [ArticleID] => 267647 [Title] => Evidence mounts for gut worm therapy [Summary] => Two sets of findings presented at the 2004 Digestive Disease Week meeting lend strength to the belief that helminthic therapy may be a highly effective treatment for inflammatory bowel disease (IBD) in a double-blind, randomized, placebo-controlled study that included 54 patients with ulcerative colitis (UC), approximately 50 percent of the patients responded to Trichurisuis ova therapy.

In addition, in an open-label study of 29 patients with refractory Crohn’s disease (CD), 79.3 percent of the subjects responded to treatment, and 72.4 percent achieved clinical remission. [DatePublished] => 2005-01-02 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with